Iradimed Corp

Health Care
Medical/Dental Instruments
www.iradimed.com

Earnings Score
Moat Score

Market Cap $648.04M
PE 33
Debt -
Cash $50.33M
EV -
FCF $14.60M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$19.78M
EBIT	$24.98M
ROE	22%
ROA	25%
FCF	$14.60M
Equity	$90.05M
Growth Stability	25%
PE	32.75
PEG	0.53
PB	7.2
P/FCF	44.38
P/S	8.62
Price/Cash	0.08
Net Margins	24%
Gross Margins	77%
Op. Margins	33%
Earnings CAGR	24%
Sales Growth YoY	11%
Sales Growth QoQ	1%
Sales CAGR	13%
FCF CAGR	9%
Equity CAGR	14%
Earnings Stability	0.38
Earnings Growth YoY	13%
Earnings Growth QoQ	-9%

Earnings CAGR 5Y	62%
Sales CAGR 5Y	22%
FCF CAGR 5Y	16%
Equity CAGR 5Y	8%
Earnings CAGR 3Y	18%
Sales CAGR 3Y	18%
FCF CAGR 3Y	34%
Equity CAGR 3Y	11%
Market Cap	$648.04M
Revenue	$75.15M
Dividend Yield	1%
Payout Ratio	40%
Assets	$101.73M
Cash	$50.33M
Shares Outstanding	12.71M
Earnings Score	38%
Moat Score	97%
Working Capital	66.66M
Current Ratio	8.87
Gross Profit	$57.80M
Shares Growth 3y	0%
Equity Growth QoQ	4%
Equity Growth YoY	18%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.

SEC Filings

Direct access to Iradimed Corp (IRMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Iradimed Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Iradimed Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 24%

Stability 38%

loading chart...

Iradimed Corp Discounted Cash Flow

Fully customizable DCF calculator online for Iradimed Corp.

Years

Calculation mode

= $281M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$15M	$16M	$17M	$19M	$21M	$23M	$25M	$28M	$30M	$33M	$36M	$361M
DCF		$15M	$14M	$14M	$14M	$14M	$14M	$14M	$14M	$14M	$14M	$139M
Value	$281M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	24%	22%	2%	21%	25%	4%	22%	24%	26%	26%	24%
ROA	-	29%	4%	13%	14%	-1%	12%	19%	24%	25%	25%
ROE	-	23%	2%	15%	17%	2%	13%	17%	24%	22%	22%

Good Net Margins (24.02%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	100%	100%	25%	100%	100%	100%	100%	25%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (25%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	3%	-29%	32%	27%	-18%	32%	27%	23%	12%	22%
Earnings YoY growth	-	-4%	-93%	1K%	53%	-86%	581%	38%	34%	12%	62%
Equity YoY growth	-	-0%	3%	27%	32%	11%	18%	2%	-3%	22%	8%
FCF YoY growth	-	17%	-69%	171%	38%	-46%	100%	-17%	-33%	192%	16%